Congratulations to our clients AstronauTx and STORM Therapeutics, which were recognised at the inaugural One Nucleus Awards in London in March. AstronauTx scooped the Best Performing Primary R&D Company of the Year Award, while STORM won the One Nucleus Boston Bootcamp competition aimed at getting companies “US-ready”. AstronauTx beat off strong competition to win the […]
The nights are getting shorter and the green shoots of spring are emerging – and it’s an exciting time for Optimum Strategic Communications as it launches Optimum TV! Our associate director and former national newspaper journalist Stephen Adams will be presenting regular YouTube episodes showcasing our clients’ amazing work. Heidelberg grabs orphan designation Heidelberg […]
Novo Holdings leads Clasp Therapeutics’ $150m fundraiser Novo Holdings co-led Clasp Therapeutics’ $150 million fundraiser to develop precision immune-oncology using next-generation T-cell engagers. Clasp is leveraging advances made by its scientific founders at Johns Hopkins University, including leading cancer geneticist and HHMI investigator Bert Vogelstein, M.D., and immuno-oncology pioneer Drew Pardoll, M.D., Ph.D., who have […]
AstraZeneca buys Novo Holdings portfolio company Amolyt in potential $1bn+ deal Novo Holdings A/S and Sofinnova Partners, two leading life sciences investors, made headlines on Thursday when portfolio company Amolyt Pharma entered into a definitive agreement to be acquired by AstraZeneca at a purchase price of US$800 million upfront and a potential milestone payment of […]
Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]
